HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Josefin Snellman Selected Research

erenumab

4/2024Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial.
3/2024Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
2/2024Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab.
1/2024Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
12/2023Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans.
1/2023Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
8/2022Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
6/2022Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
12/2019Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
12/2019Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Josefin Snellman Research Topics

Disease

16Migraine Disorders (Migraine)
03/2024 - 01/2019
7Headache (Headaches)
01/2024 - 01/2019
2Migraine without Aura (Common Migraine)
01/2024 - 10/2021
1Flushing
04/2024
1Erythema
04/2024
1Rosacea (Acne Rosacea)
04/2024
1Hypersensitivity (Allergy)
01/2021

Drug/Important Bio-Agent (IBA)

10erenumabIBA
04/2024 - 12/2019
8Calcitonin Gene-Related PeptideIBA
04/2024 - 01/2019
7Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA
04/2024 - 12/2019
5Monoclonal AntibodiesIBA
04/2024 - 01/2019
3Peptides (Polypeptides)IBA
01/2022 - 10/2020
3Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
01/2022 - 10/2020
2BMS204352IBA
10/2021 - 10/2020
2CalciumIBA
10/2021 - 10/2020
2PotassiumIBA
10/2021 - 10/2020
2Adenylyl Cyclases (Adenylyl Cyclase)IBA
01/2021 - 10/2020
1Calcitonin Gene-Related Peptide Receptor AntagonistsIBA
02/2024
1KATP ChannelsIBA
01/2024
1Cromakalim (Levcromakalim)IBA
01/2024
1Adenosine Monophosphate (AMP)IBA
12/2023
1Cilostazol (Pletal)FDA LinkGeneric
12/2023
1Potassium Channels (Potassium Channel)IBA
10/2021
1Protein Isoforms (Isoforms)IBA
10/2020
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
10/2020

Therapy/Procedure

2Intravenous Infusions
01/2021 - 10/2020
1Subcutaneous Injections
01/2024
1Therapeutics
12/2021